340B Insights
Why Independent Oversight Matters in Vendor-Managed 340B Programs
At GCA340B, staying ahead of the compliance curve isn’t just a priority—it’s the promise we make to every Covered Entity we serve. Compliance and auditing are at the heart of everything we do, and our partnership with Virtue340B further strengthens that foundation. Together, we create a unified front that helps our clients uncover vulnerabilities before…
Read MoreAlbany Med v. HRSA: What the Decision Really Means for 340B Child Site Eligibility
A federal court ruling in Albany Med v HRSA is reshaping how 340B child site eligibility is evaluated. While registration may no longer define eligibility, organizations must now clearly document and defend how sites qualify under the program.
Read MoreVirtue 340B partners with HANYS Marketplace
Virtue 340B partners with HANYS Marketplace to support hospital leaders with independent 340B compliance insight and oversight clarity Virtue 340B® has partnered with HANYS Marketplace®, a for-profit subsidiary of the Healthcare Association of New York State, to support hospitals and health systems in strengthening program oversight and turning operational complexity into clear, executive-level insight. About HANYS…
Read MoreWhy 340B Matters: A Response to PhRMA’s Middleman Narrative
This blog offers a clear, evidence-based response to that narrative by outlining what the 340B program actually does, who it serves, and why it remains indispensable for underserved patients and the safety-net providers who care for them.
Read MorePlanning for Change: The Intersection of IRA Maximum Fair Price and the 340B Rebate Policies
The IRA’s Maximum Fair Price and HRSA’s 340B rebate pilot are set to reshape drug reimbursement in 2026. Learn how covered entities can prepare, prevent duplication, and stay compliant.
Read More340B Rebate Pilot: Why Purchase Data Isn’t the Right Tool for Duplicate Discount Prevention
As the 340B rebate pilot approaches its January 2026 launch, some argue that requiring purchase data will prevent duplicate discounts. But in practice, this approach introduces complexity, misaligned timing, and inconsistent reporting. Transactional claim data remains the most accurate and reliable method for identifying duplicate discounts, ensuring compliance, and maintaining program integrity — without undermining the pilot’s core goals.
Read MoreReflections from the 2025 MDRP Summit
At the 2025 MDRP Summit, one theme was clear: collaboration between manufacturers, states, and covered entities is essential, but today’s systems often inflate disputes and obscure the true value of 340B. Katy reflects on why better communication, accurate data, and good-faith engagement are critical to protecting patient care.
Read MoreThe Benefits of 340B Consulting For Drug Pricing Program
Proactive 340B audit readiness turns compliance into a strategic advantage, boosting data accuracy, oversight, and program performance.
Read MoreWhat to Look for in a Top 340B Consultant, Firm, or Auditor: Interview Questions to Ask
Choosing the wrong 340B auditor can cost covered entities more than fees, it risks HRSA findings and compliance gaps. Learn how to vet the right, independent, knowledgeable partners who protect compliance and optimize program performance.
Read MoreFrom Zero to 340B: My First 90 Days at Virtue
New to 340B? You’re not alone. In this honest and encouraging Q&A, Jenna shares her first 90 days at Virtue 340B, from navigating acronyms to building training tools from scratch. A must-read for anyone stepping into 340B for the first time.
Read More